close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.22 +1.18 (+2.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,104,742
Open 50.30
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 50.04
Today's Range 50.25 - 51.24
52wk Range 34.10 - 51.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer
From Genentech
Via Business Wire
News headline image
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
From Genentech
Via Business Wire

Performance

YTD
+46.6%
+46.6%
1 Month
+13.9%
+13.9%
3 Month
+25.0%
+25.0%
6 Month
+27.5%
+27.5%
1 Year
+44.1%
+44.1%

More News

Read More
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
Via The Motley Fool
News headline image
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗
Via The Motley Fool
News headline image
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock ↗
Via Benzinga
News headline image
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗
Via Stocktwits
News headline image
Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why ↗
Via Benzinga
News headline image
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗
Via Investor's Business Daily
Topics Government
News headline image
2 No-Brainer Healthcare Stocks to Buy Now ↗
Via The Motley Fool
News headline image
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
From Genentech
Via Business Wire
News headline image
Magnificent Seven Will Become Low-Profit Tech Utilities, Analyst Warns ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗
Via Investor's Business Daily
News headline image
Why Roche Holding Stock Popped Today ↗
Via The Motley Fool
News headline image
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗
Via Investor's Business Daily
News headline image
Multimodal AI Unleashes New Era in Cancer Research: A Revolution in Diagnosis and Treatment
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
From Genentech
Via Business Wire
News headline image
Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. ↗
Via Investor's Business Daily
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
From Genentech
Via Business Wire
News headline image
Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
From Genentech
Via Business Wire
News headline image
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
News headline image
Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
From Genentech
Via Business Wire
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
Via Benzinga
News headline image
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗
Via Benzinga
News headline image
S&P 500's Resurgence: A Deep Dive into Market Dynamics and Future Trajectories
Via MarketMinute
Topics Artificial Intelligence Bonds Economy

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?
Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.
What exchange does Roche Holding AG Basel American Depositary Shares trade on?
Roche Holding AG Basel American Depositary Shares trades on the OTC Traded
What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?
The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded
What is the current price of Roche Holding AG Basel American Depositary Shares?
The current price of Roche Holding AG Basel American Depositary Shares is 51.22
When was Roche Holding AG Basel American Depositary Shares last traded?
The last trade of Roche Holding AG Basel American Depositary Shares was at 12/15/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today